Trial Profile
A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed With Uncomplicated Plasmodium Falciparum Malaria
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Meplazumab (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- Sponsors Pacific Meinuoke Biopharmaceutical
- 21 Feb 2024 Planned initiation date changed from 15 Dec 2023 to 15 Mar 2024.
- 18 Sep 2023 New trial record